Clinical trial · Interventional
Talc Pleurodesis in Patients With Recurrent Malignant Pleural Effusion
Analysis of Clinical and Radiological Results of Two Methods of Talc Pleurodesis in Patients With Recurrent Malignant Pleural Effusion
NCT00789087CI-TRIAL-00001774completedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to analyze and compare radiological lung expansion after talc pleurodesis performed either by videothoracoscopy or chest tube and correlate it with clinical outcome. Secondary endpoints evaluated were: clinical efficacy, safety, quality of life and survival.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Recurrent Malignant Pleural Effusion. | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Talc slurry through a chest tube (DT). | Procedure | — | UNRESOLVED |
| Videothoracoscopic talc poudrage (VT). | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- 1. Videothoracoscopic talc poudrage (VT)
- interventionNames
- Procedure: Videothoracoscopic talc poudrage (VT).
- type
- ACTIVE_COMPARATOR
- label
- 2. Talc slurry through a chest tube (DT)
- interventionNames
- Procedure: Talc slurry through a chest tube (DT).
Primary outcomes (1)
- measure
- Radiological lung expansion after talc pleurodesis and clinical outcome
- timeFrame
- 6 months
Secondary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Malignant pleural effusion confirmed by cytological analysis of pleural fluid and/or pleural biopsy; * Recurrent pleural effusion with symptoms; * Chest radiography with lung expansion after thoracocentesis; * Karnofsky Performance Status \> 70; * Written informed patient consent were obtained. Exclusion Criteria: * Hemorrhagic diathesis; * Active infection; * Cutaneous infiltration; * Patients unable to understand the questionnaires; * Age: \> 90 yo or \< 18 yo.
References
Publications (1)
- DERIVEDTerra RM, Junqueira JJM, Teixeira LR, Vargas FS, Pego-Fernandes PM, Jatene FB. Is full postpleurodesis lung expansion a determinant of a successful outcome after talc pleurodesis? Chest. 2009 Aug;136(2):361-368. doi: 10.1378/chest.08-2448. Epub 2009 Apr 6. PMID 19349389